Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15572368rdf:typepubmed:Citationlld:pubmed
pubmed-article:15572368lifeskim:mentionsumls-concept:C0021080lld:lifeskim
pubmed-article:15572368lifeskim:mentionsumls-concept:C0010592lld:lifeskim
pubmed-article:15572368lifeskim:mentionsumls-concept:C0021079lld:lifeskim
pubmed-article:15572368lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:15572368lifeskim:mentionsumls-concept:C1524075lld:lifeskim
pubmed-article:15572368lifeskim:mentionsumls-concept:C1709915lld:lifeskim
pubmed-article:15572368lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:15572368lifeskim:mentionsumls-concept:C0337112lld:lifeskim
pubmed-article:15572368pubmed:issue6lld:pubmed
pubmed-article:15572368pubmed:dateCreated2005-2-7lld:pubmed
pubmed-article:15572368pubmed:abstractTextTo dissect the enzyme inhibitory properties of the immunosuppressive cyclic undecapeptide cyclosporin A (CsA) and gain access to monospecific, non-calcineurin-inhibiting CsA derivatives, [D-Ser8]CsA was subjected to modifications at the D-Ser side chain. Thus, we modified a CsA residue flanking the calcineurin (CaN) and cyclophilin 18 (Cyp18) binding domains of CsA instead of the residues of the CaN binding domain in order to develop a new specificity-determining site within the cyclic peptide. The [O-(NH2 (CH2)5NHC(O)CH2)-D-Ser8]CsA (derivative 9), with an amino group on a tether, exhibits CsA-like inhibition of the peptidyl prolyl cis/trans isomerase activity of Cyp18 with an IC50 value of 3.2 nm, whereas the CaN inhibition by the Cyp18-derivative 9 complex is completely abolished. Consequently, this compound is not able to inhibit the proliferation and cytokine production of activated T cells. Structure-activity relationship studies with a series of [d-Ser(8)]CsA derivatives indicate that the positively charged side chain is an essential requirement for Cyp18-derivative 9 to be ineffective on CaN. Upon protecting the amino group in derivative 9 with the photolabile moiety 2-nitroveratryloxycarbonyl (NVOC), the Cyp18-[O-(NVOC-NH(CH2)5NHC(O)CH2)-D-Ser8]CsA (derivative 11) complex exhibits strong CaN inhibition and shows potent immunosuppressive activity. In stimulated T cells pretreated with derivative 11, a remarkable recovery of transcriptional activation of the nuclear factor of activated T cells (NFAT) has been achieved through light irradiation, as assessed with a NFAT reporter gene assay.lld:pubmed
pubmed-article:15572368pubmed:languageenglld:pubmed
pubmed-article:15572368pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15572368pubmed:citationSubsetIMlld:pubmed
pubmed-article:15572368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15572368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15572368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15572368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15572368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15572368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15572368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15572368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15572368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15572368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15572368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15572368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15572368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15572368pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15572368pubmed:statusMEDLINElld:pubmed
pubmed-article:15572368pubmed:monthFeblld:pubmed
pubmed-article:15572368pubmed:issn0021-9258lld:pubmed
pubmed-article:15572368pubmed:authorpubmed-author:FischerGunter...lld:pubmed
pubmed-article:15572368pubmed:authorpubmed-author:SchutkowskiMi...lld:pubmed
pubmed-article:15572368pubmed:authorpubmed-author:ZhangYixinYlld:pubmed
pubmed-article:15572368pubmed:authorpubmed-author:BaumgrassRiaRlld:pubmed
pubmed-article:15572368pubmed:authorpubmed-author:ErdmannFrankFlld:pubmed
pubmed-article:15572368pubmed:issnTypePrintlld:pubmed
pubmed-article:15572368pubmed:day11lld:pubmed
pubmed-article:15572368pubmed:volume280lld:pubmed
pubmed-article:15572368pubmed:ownerNLMlld:pubmed
pubmed-article:15572368pubmed:authorsCompleteYlld:pubmed
pubmed-article:15572368pubmed:pagination4842-50lld:pubmed
pubmed-article:15572368pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:meshHeadingpubmed-meshheading:15572368...lld:pubmed
pubmed-article:15572368pubmed:year2005lld:pubmed
pubmed-article:15572368pubmed:articleTitleUnexpected side chain effects at residue 8 of cyclosporin a derivatives allow photoswitching of immunosuppression.lld:pubmed
pubmed-article:15572368pubmed:affiliationMax Planck Research Unit for Enzymology of Protein Folding, Weinbergweg 22, D-06120, Halle/Saale, Germany.lld:pubmed
pubmed-article:15572368pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15572368pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15572368lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15572368lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15572368lld:pubmed